Diseases of liver. Liver disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: oral Detoxil capsules 400mg, 1 capsule, every 12 hours for 5 days. Detoxil capsules are prepared by Tabib-Daru Pharmaceutical Company (located at Kashan) and contai
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 80 Years
Inclusion criteria
Inclusion criteria: The patient has informed and free written consent to participate in the study; Age between 18-80; The patient's Child-Pugh score is category B or C;
Exclusion criteria
Exclusion criteria: Pregnancy; Breastfeeding; Participate in another clinical trial at the same time; History of previous allergies to any of the components of the drug;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AST serum level. Timepoint: Before and after intervention. Method of measurement: Blood sample.;ALT serum level. Timepoint: Before and after intervention. Method of measurement: Blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bilirubin serum level. Timepoint: Before and after the intervention. Method of measurement: Blood sample.;Child-Pugh score. Timepoint: Before and after the intervention. Method of measurement: Child-Pugh score classification. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParisa Kianpour
Tehran University of Medical Sciences
Outcome results
None listed